Core Viewpoint - The ongoing debate between two major companies regarding the restructuring of collagen detection methods highlights the industry's need for standardized testing protocols and the challenges posed by varying product quality in the market [1][4][6]. Group 1: Company Actions and Statements - Huaxi Biological published an article asserting the need for industry standards based on testing results, revealing that their product "Runbaiyan" was tested for collagen content using advanced HPLC-HRMS technology, yielding a result of 0.60 mg/g (0.06%) for type III collagen [2][3]. - Huaxi Biological emphasized that their testing method effectively eliminates matrix interference and ensures accurate detection of recombinant collagen, addressing concerns about the reliability of their results [2][3]. - Juzhi Biological acknowledged the limitations of their existing quality standards and testing methods, stating the need for continuous optimization to meet industry advancements and consumer expectations [5][6]. Group 2: Industry Implications - The debate over collagen measurement methods has been ongoing since May, with Huaxi Biological criticizing misleading conclusions from industry reports and calling for a unified testing standard [4][6]. - Juzhi Biological has committed to collaborating with research institutions to enhance detection methods and to gradually disclose key technical parameters and quality control data to foster industry development and transparency [5]. - The lack of a unified detection method has been described as a strategy to evade scrutiny, highlighting the industry's regulatory challenges and the necessity for verifiable solutions [6].

Core Viewpoint - The company, Xi'an Juzhi Biological Gene Technology Co., Ltd. (referred to as "Juzhi Biological"), has issued a statement addressing controversies surrounding its recombinant collagen product, Kefu Mei, emphasizing its commitment to quality standards and ongoing improvements in response to industry developments [1][2]. Group 1: Company Background and Standards - Juzhi Biological applied for the first domestic invention patent related to recombinant collagen in 2001, naming the innovative substance "human-like collagen" and applying for the "human-like" trademark [1]. - The company has accumulated over 20 years of technical expertise, transitioning the substance from laboratory research to industrial application [1]. - Multiple industry standards related to recombinant collagen have been established, including the 2021 "Guidelines for Naming Recombinant Collagen Biological Materials" and the 2022 medical industry standard YY/T 1849-2022 [1]. Group 2: Quality Control and Self-Inspection - The company claims that its product development and production adhere to established standards, implementing quality control measures for raw materials and products [2]. - In response to the controversies, Juzhi Biological conducted a comprehensive self-inspection of all production, testing, and labeling processes, validating different testing methods [2]. - The company acknowledged limitations in its existing quality standards and testing methods, indicating a need for continuous optimization to meet evolving industry standards [2]. Group 3: Controversy and Response - The controversy began when a beauty blogger accused Juzhi Biological's Kefu Mei product of ingredient fraud, claiming the actual collagen content was only 0.0177% [3]. - Juzhi Biological refuted these claims, stating that their testing results showed collagen content exceeding 0.1%, contradicting the blogger's assertions [3]. - The dispute centers on differing testing methods, with both parties accusing each other of using "unscientific" approaches, as there are currently no national standards for testing recombinant collagen in cosmetics [3]. Group 4: Market Impact - As of June 23, Juzhi Biological's total market value was HKD 54.83 billion, reflecting a nearly 40% decline from its peak on May 20 [4].

Group 1: Company Announcements - *ST Bosen's proposed board election is unrelated to the "Xifeng Liquor backdoor listing" rumors [1] - Anjiu Food Group has passed the listing hearing at the Hong Kong Stock Exchange [2] - Haitian Flavor Industry plans to globally issue 263,237,500 H-shares, with a price range of HKD 35.00 to HKD 36.30 [2] - Unilever (China) has undergone several business changes, with Roland Polaroid Hutabarat becoming the new legal representative [3] Group 2: Industry Developments - Laiyifen has expanded its distribution business to local chain supermarkets in South Korea, Vietnam, and Thailand, increasing its export SKU count to over 30 [1] - Starbucks China has reduced prices on dozens of products, with an average price drop of around 5 yuan for large cups [4] - The average monthly after-tax income for over 8,000 employees at Pang Donglai is approximately 9,000 yuan, with an estimated net profit of 1.5 billion yuan [7] Group 3: Product Testing Results - The collagen content in Kefu Beauty's collagen stick 1.0 was found to be only 0.02%, consistent with previous testing results [6]

Group 1 - The core finding of the tests indicates that the collagen content in the product "可复美胶原棒1.0" is only 0.02%, which is consistent with the previous test result of 0.0177% [1][2] - The testing was conducted by a more authoritative institution with a national quality inspection center, using the highest national standards for amino acid measurement [1] - The detection of sodium polyglutamate and arginine was found to be 0.10% and 0.18% respectively, with both results being consistent with previous tests [1] Group 2 - After excluding arginine and sodium polyglutamate, the total amount of detected amino acids was only 0.02%, which is significantly lower than expected [2] - The core amino acid glycine was quantitatively measured with a detection result of 0.002%, far below the product's labeled lower limit of 0.1% [2]

Group 1 - The beauty blogger "Dr. Big Mouth" (Hao Yu) raised questions about the testing results released by Giant Bio, specifically regarding the choice of testing methods and the accuracy of the results [1] - Concerns were expressed about the discrepancy between the claimed 100% homology of recombinant collagen with human collagen and the actual 86% homology based on Giant Bio's own patent [1] - The blogger highlighted the lack of a blank control in the biuret test, which is crucial for accurately measuring the presence of recombinant collagen in the formulation [1] Group 2 - Recently, the international testing company SGS declined a testing request from the blogger's team, citing the controversial nature of the tests and a desire to avoid involvement [2] - The blogger criticized SGS for its decision to return the testing request, arguing that testing institutions should uphold social responsibility beyond profit motives [2] - In response to Giant Bio's statement about the availability of its products, the blogger encouraged legal entities to collect samples for future consumer protection efforts [2]

Core Viewpoint - The company, Juzi Biotechnology, clarified that its product, Kefu Mei, contains genuine recombinant collagen and denied allegations of false advertising and misleading consumers [1] Group 1 - Juzi Biotechnology announced the testing results of its recombinant collagen products through Kefu Mei's Weibo account [1] - The company stated that since April 16, the Kefu Mei Collagen Stick 2.0 has been launched, while the previous version, Kefu Mei Collagen Stick 1.0, has been sold out and is being phased out [1] - There is no truth to the rumors regarding the "quiet removal" of the Kefu Mei products, as some channels still have inventory available for sale [1]